secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001933414-26-000082
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics Q1 net loss $39.3M; FDA accepts lorundrostat NDA with Dec 22, 2026 PDUFA
--------------------------------------------------------------------------------

- Net loss $39.3M for Q1 2026 vs $42.2M Q1 2025; cash $646.1M, sufficient into 2028.
- FDA accepted NDA for lorundrostat in hypertension; PDUFA target date Dec 22, 2026.
- R&D expenses $24.4M (down 36% YoY) due to conclusion of pivotal program; G&A $21.0M (up 218% YoY) on pre-commercial costs.
- Pre-commercial activities underway: market access, medical advocacy, sales prep for potential launch.
- Conference call at 4:30 p.m. ET today; webcast available on company website.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341426000082/0001933414-26-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341426000082/mlys-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001933414-26-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer